Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2004-12-21
2009-02-03
Canella, Karen A (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S152100, C424S155100, C424S156100, C530S387100, C530S388100, C530S388800
Reexamination Certificate
active
07485296
ABSTRACT:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
REFERENCES:
patent: 4867973 (1989-09-01), Goers et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5571894 (1996-11-01), Wels et al.
patent: 5738867 (1998-04-01), Spitler
patent: 5856136 (1999-01-01), Au-young
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6207380 (2001-03-01), Billing-Medel et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6261789 (2001-07-01), Reiter et al.
patent: 6261791 (2001-07-01), Reiter et al.
patent: 6267960 (2001-07-01), Reiter et al.
patent: 6541212 (2003-04-01), Reiter et al.
patent: 6756036 (2004-06-01), Reiter et al.
patent: 6790939 (2004-09-01), Reiter et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 6825326 (2004-11-01), Reiter et al.
patent: 6881822 (2005-04-01), Reiter et al.
patent: 6960443 (2005-11-01), Reiter et al.
patent: 6979730 (2005-12-01), Reiter et al.
patent: 2002/0119157 (2002-08-01), Reiter et al.
patent: 2003/0070185 (2003-04-01), Jakobovits et al.
patent: 2003/0113820 (2003-06-01), Reiter et al.
patent: 2004/0018571 (2004-01-01), Reiter et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2005/0003465 (2005-01-01), Reiter et al.
patent: 2005/0059099 (2005-03-01), Reiter et al.
patent: 2005/0152909 (2005-07-01), Reiter et al.
patent: 2005/0169930 (2005-08-01), Reiter et al.
patent: 2005/0282187 (2005-12-01), Billing-Medel et al.
patent: WO 91/09967 (1991-07-01), None
patent: WO 98/51805 (1998-11-01), None
patent: WO 98/51824 (1998-11-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-17802).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Bowie et al (Science, 1990, 257:1306-1310).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444, see abstract in particular).
Benedict et al (J. Exp. Medicine, 2001, 193(1) 89-99).
Jiang et al (JBC, 2003, 278(7) 4763-4769).
Matsushita et al (FEBS Letters, 1999, vol. 443, pp. 348-352).
Singh et al (Glycobiology, 2001, vol. 11, pp. 587-592).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Kaiser (Science, 2006, 313, 1370).
Busken, C et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Krontiris and Capizzi (Internal Medicine, 4th Edition, Editor-in-chief Jay Stein, Elsevier Science, 1994 Chapters 71-72, pp. 699-729).
Carter, S. K. et a1. Chemotherapy of Cancer; Second edition; John Wiley & Sons : New York, 1981; appendix C.
Gu et al. (Cancer Res. 2005, 65:9495-9500).
Sharma et al. (Investigational New Drugs 1997, 15:361-364).
Singh et al. (Investigational New Drugs, 2006 24:189-194).
Thorpe, Philip E. and Walter C. I. Ross, “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates,” Immunological Review, 1982,62:119-58.
Boulianne, Gabrielle L. et al., “Productions of Functional Chimeric Mouse/Human Antibody,” Nature, Dec. 1984. 312:643-6.
Fell, H. Perry et al., “Homologous Recombination in Hybridoma Cells: Heavy Chain Chimeric Antibody Produced by Gene Targeting,” Proc. Natl. Acad. Sci. USA, Nov. 1989,86:8507-11.
Hellstrom, Ingegerd et al., “Strong Antitumor Activities of IgG3 Antibodies to a Human Melanoma-Associated Ganglioside,” Proc. Natl. Acad. Sci. USA, Mar. 1985.82:1499-1502.
Hellstrom, Karl Erik and Ingegerd Hellstrom, “Antibody for Drug Delivery,” in Robinson et al., eds, Controlled Drug Delivery, 2nd edition, Marcel Dekker, Inc. 1987. 623-53.
Neuberger, Michael S. et al., “Recombinant Antibodies ,Possessing Novel Effector Functions,” Nature, Dec. 13, 1984.312:604-8.
Sahagan, Barbara G. et al., “A Genetically Engineered MurinelHuman Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen,” The Journal of Immunology, Aug. 1, 1986, 137:1066-74.
Sharon, J., et al., “Expression of a VHCK Chimeric Protein in Mouse Myeloma Cells,” Nature, May 1984, 309:364-7.
Shizuya, Hiroaki et al., “Cloning and Stable Maintenance of 300-Kilobase-Pair Fragments of Human DNA inEscherichia coliUsing an F-Factor-Based Vector,” Proc. Natl. Acad. Sci., USA, Sep. 1992. 89:8794-7.
Tan, Lee K. et al, “A Human-Mouse Chimeric Immunoglobulin Gene With a Human Variable-Region is Expressed in Mouse Myeloma Cells,” The Journal of Immunology, Nov. 1985, 135:3564-7.
Algate, Paul A. et al., “Regulation of the Interleukin-3 (IL-3) Receptor by IL-3 in the Fetal Liver-Derived FL5.12 Cell Line,” Blood, May 1994, 83(9):2459-68.
Amon, Ruth et al., “Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy,” Monoclonal Antibodies and Cancer Therapy, Reisfield, Ralph A. and Stewart Sell (eds.) 1985,243-56.
Bacchetti, Silvia and Frank I. Graham, “Transfer of the Gene for Thymidine Kinase to Thymidine Kinase-Deficient Human Cells by Purified Herpes Simplex Viral DNA,” Proc. Natl. Acad. Sci. USA, Apr. 1977. 74(4):1590-4.
Berent, Susan L. et al., “Comparison of Oligonucleotide and Long DNA Fragments as Probes in DNA and RNA Dot, Southern, Northern, Colony and Plaque Hybridizations,” BioTechniques, May/Jun. 1985, 3:208-19.
Berkner, Kathleen I., ˜Development of Adenovirus Vectors for the Expression of Heterologous Genes, BioTechniques, Jul./Aug. 1988, 6(7):616-29.
Bonkhoff, Helmut and Klaus Remberger, “Differentiation Pathways and Histogenetic Aspects of Normal and Abnormal Prostatic Growth: A Stem Cell Model,” The Prostate, Feb. 1996.28(2):98-106.
Bonkhoff, Helmut et al., “The Proliferative Function of Basal Cells in the Normal and Hyperplastic Human Prostate,” The Prostate, Jan. 1994, 24( 1 ): 114-8.
Boshart, Michael et al., “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,” Cell, Jun. 1985, 41(2):521-30.
Breviario, Ferruccio et al., “Interleukin-1-Inducible Genes in Endothelial Cells Cloning of a New Gene Related to C-Reactive Protein and Serum Amyloid P Component,” The Journal of Biological Chemistry, Nov. 5, 1992,267(31):22190-7.
Brinster, Ralph I. et al., “Transgenic Mice Harboring SV40 T-Antigen Genes Develop Characteristic Brain Tumors,” Cell, Jun. 1984, 37:367-79.
Brinster, Ralph L. et al., “Introns Increase Transcriptional Efficiency in Transgenic Mice,” Proc. Natl. Acad. Sci. USA, Feb. 1988, 85:836-40.
Cluitmans, F.H.M. et al., “IL-4 Down-Regulates IL-2-, IL-3-, and GM-CSF-Induced Cytokine Gene Expression in Peripheral Blood Monocytes,” Annals of Hematology, 1994, 68:293-8.
De Wit, Harry et al., “Differential Regulation of M-CSF and IL-6 Gene Expression in Monocytic Cells,” British Journal of Hematology, 1994, 86:259-64.
DePamphilis, M.L. et al., “Microinjecting DNA into Mouse Ova to Study DNA Replication and Gene Expression and to Produce Transgenic Animals,” BioTechniques, Jul./Aug. 1988, 6(7):662-80.
Espinoza-Delgado, Igor, et al, “Regulation of IL-2 Receptor Subunit Genes in Human Monocytes Differential Effects ofIL-2 and IFN-y,” The Journal of Immunology, Nov. 1, 1992. 149(9):2961-8.
Felgner, Philip L. et al., “Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure,” Proc. Natl. Acad. Sci. USA, Nov. 1987. 84:7413-7.
Felgner, P.L. et al., “Cationic Liposome Mediated Transfection,” Proceedings of the Western Pharmacology Society, 1989.32:115-
Jakobovits Aya
Reiter Robert E.
Saffran Douglas C.
Witte Owen N.
Agensys, Inc.
Canella Karen A
Reddig Peter J
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
PSCA: prostate stem cell antigen and uses thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PSCA: prostate stem cell antigen and uses thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PSCA: prostate stem cell antigen and uses thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093921